« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 119, Issue 1
, Pages
199-205
, January 2007
Egg oral immunotherapy in nonanaphylactic children with egg allergy
Supported by the University of Arkansas for Medical Sciences Chancellor's Research Fund and the Arkansas Children's Hospital Pediatric Clinical Research Unit, as well as the Duke General Clinical Research Center, grant 5M01-RR-000030-45, National Center for Research Resources, Clinical Research Centers Program, and National Institutes of Health.Disclosure of potential conflict of interest: S. M. Jones has received grant support from the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, Dyax, Mead Johnson, Merck, GlaxoSmithKline, Novartis, Genentech, AstraZeneca, and Aventis. L Christie has consulting arrangements with the Food Allergy and Anaphylaxis Network. P. H. Steele is on the speakers' bureau for Sepracor Pharmaceuticals. A. W. Burks has consultant arrangements with Genentech; owns stock in Seer, Inc; has patent licensing arrangements on peanut allergens and Methods, Isolated, and Purified Ara H2 antigen for producing mAbs for Ara h 2; and has received grant support from NCRR and the National Institutes of Health; and is on the speakers' bureau for Novartis and Dey. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(06)01938-5
doi: 10.1016/j.jaci.2006.09.016
© 2007 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 119, Issue 1
, Pages
199-205
, January 2007
